GCF PLAP-1, Sclerostin and TNF-α Levels in Periodontitis
Gingival Crevicular Fluid Periodontal Ligament-related Protein-1, Sclerostin and Tumor Necrosis Factor-alfa Levels in Periodontitis
1 other identifier
observational
71
1 country
1
Brief Summary
Periodontal ligament-associated protein-1 (PLAP-1) and sclerostin play an important role in the suppression of bone formation. Tumor necrosis factor-alpha (TNF-α) is an important proinflammatory cytokine involved in periodontal bone loss. This study aims to investigate gingival crevicular fluid (GCF) PLAP-1, sclerostin and TNF-α levels in individuals with periodontal disease. Totally 71 systemically healthy and non-smoker individuals consisting of stage 3 grade C periodontitis (n=23), gingivitis (n=24) and periodontally healthy (n=24) were enrolled. Periodontal status was evaluated by measuring the full-mouth clinical periodontal parameters. GCF PLAP-1, sclerostin and TNF-α total amounts were measured by ELISA. Data were analyzed using non-parametric statistical tests.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Sep 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 20, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
June 15, 2021
CompletedFirst Submitted
Initial submission to the registry
December 8, 2022
CompletedFirst Posted
Study publicly available on registry
December 20, 2022
CompletedDecember 20, 2022
December 1, 2022
8 months
December 8, 2022
December 8, 2022
Conditions
Outcome Measures
Primary Outcomes (3)
GCF PLAP-1 levels
ng
24 hours after clinical periodontal measurements
GCF sclerostin levels
ng
24 hours after clinical periodontal measurements
GCF TNF-α levels
ng
24 hours after clinical periodontal measurements
Study Arms (3)
Stage 3 Grade C Periodontitis
Generalized S3GC periodontitis patients had PD ≥ 6 mm and interproximal CAL ≥ 5 mm and with radiographic alveolar bone loss extending at least to the middle third of the root at 30 % of the teeth or more. These patients showed no more than four teeth loss due to periodontitis. The percentage bone loss/age values in this group were \> 1.0
Gingivitis
Gingivitis patients exhibited PD ≤ 3 mm and no interproximal CAL or radiographic bone loss. These patients had BOP ≥ 30% of probe sites.
Periodontal health
Periodontally healthy controls had an intact periodontium or a reduced periodontium in a non-periodontitis patient (without interproximal CAL or radiographic bone loss). PD was ≤ 3 mm and BOP was \< 10 % in this group.
Interventions
Periodontal clinical parameters measurements probing depth (PD), clinical attachment loss (CAL), the dichotomous recording (present/absent) of bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were recorded at six sites (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, and disto-lingual) per tooth, except the third molars using a manual periodontal probe. A sterile paper strip was gently placed into the gingival sulcus/periodontal pocket until mild resistance was sensed and left in place for 30 seconds.
Eligibility Criteria
A total of 71 systemically healthy and never-smoker individuals (34 males and 37 females and; aged 27 to 46 years) were consecutively included for this cross-sectional study.
You may qualify if:
- no history of smoking (determined by self-reporting)
- had a minimum of 18 natural remaining teeth (excluding third molars).
You may not qualify if:
- suffered from diabetes mellitus, rheumatoid arthritis, cardiovascular and respiratory system diseases, hepatic and renal failure, metabolic bone diseases, endocrine disorders, immunologic and mucocutaneous diseases
- used immunosuppressive agents, antibiotics, anti-inflammatory and anti-resorptive drugs, topical antiseptic solutions, calcium channel blockers, beta-blockers, anticoagulants and hormonal contraceptives within the past 3 months
- pregnant or lactating
- received any periodontal intervention in the past year
- used removable partial dentures or orthodontic appliances
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Adnan Menderes University, Faculty of Dentistry, Department of Periodontology
Aydin, 09100, Turkey (Türkiye)
Related Publications (1)
Gur B, Afacan B, Cevik O, Kose T, Emingil G. Gingival crevicular fluid periodontal ligament-associated protein-1, sclerostin, and tumor necrosis factor-alpha levels in periodontitis. J Periodontol. 2023 Oct;94(10):1166-1175. doi: 10.1002/JPER.22-0750. Epub 2023 Apr 19.
PMID: 37006132DERIVED
Biospecimen
Gingival crevicular fluid
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Berkay Gür
Aydin Adnan Menderes University
- PRINCIPAL INVESTIGATOR
Özge Çevik
Aydin Adnan Menderes University
- PRINCIPAL INVESTIGATOR
Timur Köse
İzmir Ege University
- PRINCIPAL INVESTIGATOR
Gülnur Emingil
İzmir Ege University
- STUDY DIRECTOR
Beral Afacan
Aydin Adnan Menderes University
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
December 8, 2022
First Posted
December 20, 2022
Study Start
September 20, 2020
Primary Completion
June 1, 2021
Study Completion
June 15, 2021
Last Updated
December 20, 2022
Record last verified: 2022-12